CN1270029A - 可控释活性物质的阿片样止痛药 - Google Patents
可控释活性物质的阿片样止痛药 Download PDFInfo
- Publication number
- CN1270029A CN1270029A CN00104523A CN00104523A CN1270029A CN 1270029 A CN1270029 A CN 1270029A CN 00104523 A CN00104523 A CN 00104523A CN 00104523 A CN00104523 A CN 00104523A CN 1270029 A CN1270029 A CN 1270029A
- Authority
- CN
- China
- Prior art keywords
- formulation according
- release
- crystal
- coating
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000202 analgesic effect Effects 0.000 title claims description 27
- 239000013078 crystal Substances 0.000 claims abstract description 56
- 238000013270 controlled release Methods 0.000 claims abstract description 35
- 239000011247 coating layer Substances 0.000 claims abstract 6
- 239000000014 opioid analgesic Substances 0.000 claims abstract 6
- 239000002245 particle Substances 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims description 41
- 238000000576 coating method Methods 0.000 claims description 38
- 239000011248 coating agent Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 16
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 9
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- -1 oxyhydrocodone Chemical compound 0.000 claims description 8
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 6
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229960004380 tramadol Drugs 0.000 claims description 6
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 6
- 229960005181 morphine Drugs 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 2
- 229920013820 alkyl cellulose Polymers 0.000 claims description 2
- 229960001736 buprenorphine Drugs 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229960002428 fentanyl Drugs 0.000 claims description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229960001797 methadone Drugs 0.000 claims description 2
- 229960005195 morphine hydrochloride Drugs 0.000 claims description 2
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 claims description 2
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 claims description 2
- 229960000482 pethidine Drugs 0.000 claims description 2
- RBOXVHNMENFORY-UHFFFAOYSA-N 9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol Chemical compound C1C(N(CCC234)C)C2CCC(O)C3OC2=C4C1=CC=C2OC RBOXVHNMENFORY-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229920006215 polyvinyl ketone Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 abstract 1
- 239000008896 Opium Substances 0.000 description 18
- 229960001027 opium Drugs 0.000 description 18
- 239000000463 material Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 5
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229920003086 cellulose ether Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000005354 coacervation Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 1
- 229960001286 piritramide Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种含有晶体形式的阿片样止痛药的口服控释制剂,其中所述晶体具有的颗粒大小为10μm—3mm,它具有至少一种控释包衣层。
Description
本发明涉及一种口服给药的药物制剂，从该制剂中可以控释阿片样止痛活性物质。
从现有技术中可以得知具有控释活性物质的止痛药的许多制剂。
尤其是EP-A-0647448由此已经描述了一种活性物质缓释的止痛活性制剂，它由大量基质组成，所述的基质含有0.1-3mm直径的控释阿片样止痛药作为单一日剂量。适于这种目的的基质可以形成球状体、微珠、小丸或颗粒。这类基质的制备要求相对完善的配制方法，诸如用于小丸的层粘连凝聚法或用于球状体的挤压/成球法。
另一方面，许多阿片样活性物质在它们被制备时以晶体形式出现，使得存在一种直接使用它们的需求，即在药物制备过程中不需要所规定的完善配制方法。
因此，本发明的目的是提供一种含有至少一种阿片样活性物质的口服控释制剂，其中可以直接使用在制备活性物质过程中获得的晶体，即不需要完善的配制步骤。
按照本发明，通过提供控释晶体形式的阿片样止痛药的口服给药制剂可以达到这一目的，其中所述的晶体具有10μm-3mm的颗粒大小，它具有至少一种控释包衣层。
所述的晶体优选具有50μm-1mm的颗粒大小。
本发明的制剂含有至少一种晶形的阿片样止痛药作为止痛活性物质。可以使用的阿片样止痛药是二氢吗啡酮、羟氢可待酮、吗啡、羟甲左吗喃、美沙酮、二氢可待因、可待因、二氢吗啡、哌替啶、芬太尼、氰苯双哌酰胺、丁丙诺啡、胺苯环己乙酯、曲马多、其特定的盐或其混合物。
特别优选将曲马多、盐酸曲马多、吗啡、盐酸吗啡和/或硫酸吗啡用作止痛药。
本发明制剂中的活性物质晶体可以是单晶或具有多晶结构。
除所述的阿片样止痛药外，本发明的制剂可以含有任意与阿片样止痛药表现出协同作用的非阿片样止痛药。这些非阿片样止痛药包括布洛芬、酮基布洛芬、氟比洛芬、异丙基安替比林、对乙酰氨基酚、萘普生、醋炎痛(acematacin)、阿司匹林、安乃近及其盐，优选它们的晶体形式。
本发明所用的制剂以控释、优选缓释所述的止痛药为特征。
通过提供具有至少一种控释包衣层的活性物质晶体可以达到这一目的。这种包衣层可确保所述的活性物质在所需期限内控释或缓释。与常规剂型、即那些没有控释包衣层的剂型相比，在这种方式中，能够有目的地控制起作用的时间期限。优选尽力以这样一种方式调整活性物质的释放，使得需要将所述的制剂每日至多给药两次、优选仅给药一次。
合适的包衣材料是任意的药物上安全的包衣材料，它们对于本领域普通技术人员来说是公知的。优选将天然的、任意修饰的或合成的聚合物用作包衣材料。这些是聚合物，诸如纤维素醚类或丙烯酸树脂类。特别优选的是：不溶于水的或水溶胀的纤维素衍生物，诸如烷基纤维素、优选乙基纤维素；或者不溶于水的丙烯酸树脂，诸如聚(甲基)丙烯酸和/或其衍生物，诸如它们的盐类、酰胺类或酯类。
从现有技术中可以得知这些物质，例如Bauer，Lehmann，Osterwald，Rothgang“Uberzogene Arzneiformen”，Wissenschaftliche VerlagsgesellschaftmbH，Stuttgart，1998，69页及其下的内容中所述，并将该文献的内容引入本文作为参考。
除不溶于水的聚合物和蜡外，还通过优选使用高达30wt.％的非控释、优选诸如聚乙烯吡咯烷酮这样的水溶性聚合物或诸如羟乙基纤维素、羟丙基甲基纤维素或羟丙基纤维素这样的水溶性纤维素衍生物和/或公知的增塑剂也能够任意调整活性物质的释放速率。
除控释包衣层外，所述活性物质的晶体还可以含有另外的包衣层。
例如，可以将这类非控释的包衣材料的包衣材料涂布在所述的晶体表面上作为非控释的中间层。
优选用于这种中间层的包衣材料是纤维素醚类、聚乙烯酮类、聚丙烯酸酯类或者也可以是天然的聚合物。
还能够由活性物质晶体或由优选不同于所述活性物质的阿片样止痛药而优选在控释包衣层上制备另外的包衣层，在口服给药后这种活性物质以一种非控释的方式从该包衣层中被释放出来。通过这种多层包衣，能够在将所述的制剂
给药后提供一种主要用于迅速缓解疼痛的初级剂量，其中由随后延缓释放的活性物质可以维持止痛药的水平。可用于这种目的的包衣材料是药物上安全的物质与最初的活性物质，诸如纤维素醚类、聚乙烯酮类、聚丙烯酸酯类。然而，除活性物质晶体或不同于该活性物质的另外的止痛药(优选阿片样止痛药)外，还能够在非控释包衣层中提供另一种非控释的药物活性物质，或者用这一药物活性物质取代活性物质晶体或不同于该活性物质的另外的止痛药(优选阿片样止痛药)。
除控释包衣层外，所述的晶体还可以另外具有以一种pH依赖性方式溶解的包衣层。因此，例如能够确保制剂中一定比例的晶体以未溶解度方式通过胃道且到达肠道后才释放。
本发明的另一个优选的实施方案是本发明的制剂除包括含有可确保活性物质受控释放的控释包衣层和任意另外的包衣层的活性物质晶体外还包括非控释的活性物质晶体，不过，这些晶体含有一种或多种所述的非控释包衣层。
阿片样活性物质晶体的制备是公知的。在活性物质的必要纯化过程中直接获得这些晶体。
按照下列常规的公知方法在生产时、优选在重晶体后迅速获得的活性物质晶体具有包衣层：诸如通过用溶液、分散液和/或乳浊液喷雾或者通过涂粉法。凝聚法也是一种合适的方法。
为了这一目的，通过在最终的纯化步骤后对所述的活性物质晶体进行包衣而将一种中间层涂布在各晶体上、晶体化并通过用喷雾溶液或优选一种含水包衣分散体喷雾它们而进行干燥。在其上涂布控释包衣层，再次用一种包衣分散体喷涂且随后干燥。这种包衣层的厚度可以根据所到达的释放形态而改变。
如果还涂布另外的包衣层，那么优选用相同的方法制备它们。
本发明还提供了胶囊形式的本发明的口服给药制剂，其中根据所实现的止痛药的各释放期限和释放的量活性物质晶体与受控释放的阿片样止痛药共存。优选将胶囊中活性物质晶体的量进行选择以便使所述的剂量足以每日给药两次、优选一次。如果仅需要将包衣的活性物质晶体包裹在胶囊中，那么不需完善的配制方法也可以获得这种受控释放的胶囊制剂。根据本发明，还可以将所述的活性物质晶体装入小瓶或小袋形式的计量装置中或借助于一种配药器将它们按体积计量。能够添加常规的辅助剂，诸如增充剂、润滑剂或崩解促进剂。此外，本发明的口服给药制剂可以采用片剂形式，其中根据所实现的阿片样止痛药的各释放期限和释放的量将含有或不含常规片剂辅助剂或添加剂的包衣的活性物质晶体压塑成一种片剂。还是在这种情况中，有利的是是否将构成所述片剂的活性物质晶体的量进行选择以便使所实现的止痛药的释放期限和释放的量足以每日给药两次、优选一次。
优选生产含有高比例辅助剂的片剂，使得包衣的活性物质晶体以各种形式得到保留。当所述的片剂快速崩解时，所述的晶体从这种进行受控释放的片剂中被释放出来。甚至当片剂崩解时，受控释放的活性物质晶体的释放形态得到了保持。
还能够生产含有小比例辅助剂的片剂。在这种情况中，在压制时包衣的活性物质晶体相互凝集，从而形成一种附加的受控释放基质。这类片剂不再自发地崩解以便使它们具有比各包衣的晶体具有更高的延缓释放程度。
本发明制剂优选含有的曲马多总浓度以盐酸盐计算为10-1000mg、优选50-800mg。
实施例实施例1
将具有颗粒大小为250-500μm的多晶结构的盐酸曲马多晶体在将其制备和纯化后使用，不需进一步的配制步骤。所述乙基纤维素的规定量与使用含水分散体后的干重有关。组成：
| 晶体 | 盐酸曲马多 | 1.000kg |
| 包衣层 | 乙基纤维素(Aquacoat) | 0.200kg |
| 癸二酸二丁酯 | 0.050kg | |
| 总计 | 1.250kg |
在流化床设备中用热气循环这些盐酸曲马多晶体并借助于一种双相喷嘴将预先拌入癸二酸二丁酯的含水乙基纤维素悬浮液缓慢喷在所述的晶体上。一旦用完该悬浮液，晶体也就被干燥了。实施例2
将按照实施例1包衣的晶体加工制备成胶囊。
为了这一目的，在一种立方体混合器中将包衣的晶体与上述辅助剂混合并使用一种包囊机将其包入硬度为2号的胶囊中。组成：
实施例3
| 胶囊填充物 | 每粒胶囊 | 每批 |
| 盐酸曲马多晶体，按照实施例1包衣 | 125mg | 1.25kg |
| 单晶纤维素 | 75mg | 0.75kg |
| 羧甲基淀粉钠，A型 | 45mg | 0.45kg |
| 硬脂酸镁 | 5mg | 0.05kg |
| 总计 | 250mg | 2.50kg |
将按照实施例1包衣的250g晶体与344g单晶纤维素和6g硬脂酸镁混合并迅速压塑成直径为10mm且重量为300mg的崩解片。实施例4
将具有颗粒大小为250-500μm的多晶结构的盐酸曲马多晶体在将其制备和纯化后使用。涉及中间层和受控释放层的具体内容与使用含水分散体后的干重有关。
在流化床设备中用热气循环这些盐酸曲马多晶体且首先将用于生产中间层的含水分散体喷在其上并干燥。然后，借助于一种双相喷嘴将预先拌入癸二酸二丁酯的乙基纤维素悬浮液缓慢喷在所述的晶体上。一旦用完该悬浮液，晶体也就被干燥了。组成：
| 晶体 | 盐酸曲马多 | 1.000kg |
| 中间层 | Macrogol 6000 | 0.025kg |
| 滑石 | 0.040kg | |
| 羟丙基甲基纤维素，2910型，6mPas | 0.100kg | |
| 包衣层 | 乙基纤维素(Aquacoat) | 0.200kg |
| 癸二酸二丁酯 | 0.050kg |
Claims (16)
1.含有晶体形式的阿片样止痛药的口服控释制剂，其中所述晶体具有的颗粒大小为10μm-3mm，优选50μm-1mm，该制剂具有至少一种控释包衣层。
2.根据权利要求1的制剂，其特征在于所述晶体是单晶或具有多晶结构。
3.根据权利要求1或2的制剂，其特征在于所述的控释包衣层基于一种聚合物。
4.根据权利要求3的制剂，其特征在于所述的控释包衣层含有高达30wt.％的一种非控释的聚合物。
5.根据权利要求3或4的制剂，其特征在于将丙烯酸树脂和/或纤维素衍生物、优选烷基纤维素用作所述的聚合物。
6.根据权利要求3-5之一的制剂，其特征在于将乙基纤维素和/或聚(甲基)丙烯酸和/或其衍生物以及任选地高达30wt.％的羟丙基纤维素、羟甲基纤维素、羟丙基甲基纤维素或聚乙烯酮类用作所述的聚合物。
7.根据权利要求1-6之一的制剂，其特征在于将二氢吗啡酮、羟氢可待酮、吗啡、羟甲左吗喃、美沙酮、二氢可待因、可待因、二氢吗啡、哌替啶、氰苯双哌酰胺、芬太尼、胺苯环己乙酯、丁丙诺啡、曲马多、它们的特定的盐或它们的混合物用作所述的阿片样止痛药。
8.根据权利要求7的制剂，其特征在于所述阿片样止痛药是曲马多、盐酸曲马多和/或吗啡、盐酸吗啡和/或硫酸吗啡。
9.根据权利要求1-8之一的制剂，其特征在于除控释包衣层外，所述的晶体另有至少一层另外的包衣层。
10.根据权利要求9的制剂，其特征在于所述另外的包衣层包含一种直接涂布于所述晶体表面作为非控释中间层的物质的包衣层而不是控释包衣层。
11.根据权利要求9或10的制剂，其特征在于所述另外的包衣层包括一种耐胃液的包衣层。
12.根据权利要求9-11之一的制剂，其特征在于所述另外的包衣层包括一种含有阿片样止痛药的包衣层，其中所述的阿片样止痛药与所述的晶体止痛药或另一种药物活性物质相同或不同。
13.根据权利要求1-12之一的制剂，其特征在于所述的晶体存在于胶囊、小袋、小瓶、分配器、优选一种计量分配器中。
14.根据权利要求1-12的制剂，其特征在于将所述的晶体与常规的辅助剂和添加剂一起压片。
15.根据权利要求1-12的制剂，其特征在于将所述的晶体任意与非控释的药物活性物质、与或不与辅助剂和添加剂一起压成片剂。
16.根据权利要求1-15之一的制剂，其特征在于以盐酸盐计算曲马多的总浓度为10-1000mg。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19901687.9 | 1999-01-18 | ||
| DE19901687A DE19901687B4 (de) | 1999-01-18 | 1999-01-18 | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1270029A true CN1270029A (zh) | 2000-10-18 |
| CN1244327C CN1244327C (zh) | 2006-03-08 |
Family
ID=7894566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001045237A Expired - Fee Related CN1244327C (zh) | 1999-01-18 | 2000-01-17 | 可控释活性物质的阿片样止痛药 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6685964B1 (zh) |
| EP (1) | EP1020185B1 (zh) |
| JP (1) | JP2000212072A (zh) |
| KR (1) | KR20000071247A (zh) |
| CN (1) | CN1244327C (zh) |
| AR (1) | AR022254A1 (zh) |
| AT (1) | ATE257012T1 (zh) |
| AU (1) | AU771064B2 (zh) |
| CA (1) | CA2295471A1 (zh) |
| CO (1) | CO5251462A1 (zh) |
| DE (2) | DE19901687B4 (zh) |
| DK (1) | DK1020185T3 (zh) |
| ES (1) | ES2213971T3 (zh) |
| HU (1) | HUP0000138A3 (zh) |
| IL (1) | IL134076A (zh) |
| NZ (1) | NZ502261A (zh) |
| PE (1) | PE20001395A1 (zh) |
| PL (1) | PL337867A1 (zh) |
| PT (1) | PT1020185E (zh) |
| RU (1) | RU2239417C2 (zh) |
| SI (1) | SI1020185T1 (zh) |
| SK (1) | SK285129B6 (zh) |
| ZA (1) | ZA200000173B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336501C (zh) * | 2003-08-06 | 2007-09-12 | 健乔信元医药生技股份有限公司 | 醋炎痛缓释性圆粒组成物及制备方法 |
| CN106176683A (zh) * | 2016-08-31 | 2016-12-07 | 贵州益康制药有限公司 | 一种盐酸曲马多缓释胶囊及其制备方法和用途 |
| WO2024193475A1 (zh) * | 2023-03-17 | 2024-09-26 | 浙江大学 | 一种控释制剂及其制备方法 |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR101197919B1 (ko) | 1999-10-29 | 2012-11-29 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| PT1190712E (pt) * | 2000-09-22 | 2005-01-31 | Smb Technology | Composicao de esferas de tramadol para administracao oral uma vez por dia |
| US6733783B2 (en) | 2000-10-30 | 2004-05-11 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| EP1389092B1 (en) * | 2001-05-11 | 2006-11-15 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid dosage form |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| CA2476565A1 (en) * | 2002-01-23 | 2003-07-31 | The Regents Of The University Of California | Methods and compositions for reducing the development of drug tolerance and/or physical dependence |
| US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
| US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| US20040156844A1 (en) * | 2002-05-22 | 2004-08-12 | Curtis Wright | Tamper resistant oral dosage form |
| EP1555022B1 (en) * | 2002-09-21 | 2008-02-20 | Shuyi Zhang | Sustained release formulation of acetaminophen and tramadol |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| EP1610767B1 (en) | 2003-03-26 | 2011-01-19 | Egalet A/S | Morphine controlled release system |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| EP1754471A1 (de) * | 2005-08-18 | 2007-02-21 | ORAMON-Arzneimittel GmbH & Co. KG | Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung |
| DK1940467T3 (da) | 2005-09-09 | 2017-02-13 | Paladin Labs Inc | Lægemiddelsammensætning med langvarig frigivelse |
| SI1931346T1 (sl) | 2005-09-09 | 2012-10-30 | Angelini Labopharm Llc | Trazodonski sestavek za dajanje enkrat dnevno |
| US8343546B2 (en) * | 2005-09-13 | 2013-01-01 | Coating Place, Inc. | Ion exchange resin treated to control swelling |
| US7842312B2 (en) | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
| US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| EA020867B1 (ru) * | 2006-03-06 | 2015-02-27 | Поузен Инк. | Лекарственные формы для введения комбинаций лекарственных средств |
| US9265732B2 (en) * | 2006-03-06 | 2016-02-23 | Pozen Inc. | Dosage forms for administering combinations of drugs |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| GB0625646D0 (en) * | 2006-12-21 | 2007-01-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| GB0714790D0 (en) * | 2007-07-30 | 2007-09-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| CN102209529A (zh) | 2008-09-09 | 2011-10-05 | 阿斯利康(瑞典)有限公司 | 将药物组合物递送至有需要的患者的方法 |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| US20120065221A1 (en) * | 2009-02-26 | 2012-03-15 | Theraquest Biosciences, Inc. | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| AU2010266026B2 (en) * | 2009-06-25 | 2014-08-07 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company | Method for treating a patient in need of aspirin therapy |
| CN102481293A (zh) | 2009-06-25 | 2012-05-30 | 阿斯利康(瑞典)有限公司 | 治疗具有发展nsaid-相关的溃疡的风险的患者的方法 |
| MX2012012991A (es) | 2010-05-11 | 2012-11-30 | Cima Labs Inc | Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol. |
| WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| MX362838B (es) | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| KR102810926B1 (ko) | 2017-12-20 | 2025-05-22 | 퍼듀 퍼머 엘피 | 남용 억제 황산모르핀 제형 |
| US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
| JPH0759499B2 (ja) * | 1984-02-10 | 1995-06-28 | ベンツォン ファーマ エイ／エス | 拡散被覆された複合単位服用剤 |
| US5095151A (en) * | 1985-05-21 | 1992-03-10 | American Home Products Corporation | Preparation of propranolol hydrochloride macrocrystals |
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| EP0647448A1 (en) * | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Orally administrable opioid formulations having extended duration of effect |
| PT654263E (pt) * | 1993-11-23 | 2002-06-28 | Euro Celtique Sa | Metodo para a preparacao de uma composicao de libertyacao prolongada |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| AU8293498A (en) * | 1997-07-02 | 1999-01-25 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
| DE19901683B4 (de) * | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
-
1999
- 1999-01-18 DE DE19901687A patent/DE19901687B4/de not_active Expired - Fee Related
- 1999-12-21 PT PT99125470T patent/PT1020185E/pt unknown
- 1999-12-21 DK DK99125470T patent/DK1020185T3/da active
- 1999-12-21 DE DE59908195T patent/DE59908195D1/de not_active Expired - Lifetime
- 1999-12-21 EP EP99125470A patent/EP1020185B1/de not_active Expired - Lifetime
- 1999-12-21 AT AT99125470T patent/ATE257012T1/de active
- 1999-12-21 ES ES99125470T patent/ES2213971T3/es not_active Expired - Lifetime
- 1999-12-21 SI SI9930501T patent/SI1020185T1/xx unknown
-
2000
- 2000-01-05 AU AU10113/00A patent/AU771064B2/en not_active Ceased
- 2000-01-06 PE PE2000000012A patent/PE20001395A1/es not_active Application Discontinuation
- 2000-01-11 AR ARP000100111A patent/AR022254A1/es unknown
- 2000-01-11 NZ NZ502261A patent/NZ502261A/en not_active IP Right Cessation
- 2000-01-14 CA CA002295471A patent/CA2295471A1/en not_active Abandoned
- 2000-01-14 JP JP2000006879A patent/JP2000212072A/ja not_active Withdrawn
- 2000-01-15 KR KR1020000001839A patent/KR20000071247A/ko not_active Ceased
- 2000-01-17 CN CNB001045237A patent/CN1244327C/zh not_active Expired - Fee Related
- 2000-01-17 CO CO00002029A patent/CO5251462A1/es not_active Application Discontinuation
- 2000-01-17 IL IL13407600A patent/IL134076A/xx not_active IP Right Cessation
- 2000-01-17 PL PL00337867A patent/PL337867A1/xx not_active Application Discontinuation
- 2000-01-17 ZA ZA200000173A patent/ZA200000173B/xx unknown
- 2000-01-17 HU HU0000138A patent/HUP0000138A3/hu unknown
- 2000-01-17 RU RU2000101024/15A patent/RU2239417C2/ru not_active IP Right Cessation
- 2000-01-17 SK SK64-2000A patent/SK285129B6/sk not_active IP Right Cessation
- 2000-01-18 US US09/484,016 patent/US6685964B1/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336501C (zh) * | 2003-08-06 | 2007-09-12 | 健乔信元医药生技股份有限公司 | 醋炎痛缓释性圆粒组成物及制备方法 |
| CN106176683A (zh) * | 2016-08-31 | 2016-12-07 | 贵州益康制药有限公司 | 一种盐酸曲马多缓释胶囊及其制备方法和用途 |
| CN106176683B (zh) * | 2016-08-31 | 2019-04-16 | 贵州益康制药有限公司 | 一种盐酸曲马多缓释胶囊及其制备方法和用途 |
| WO2024193475A1 (zh) * | 2023-03-17 | 2024-09-26 | 浙江大学 | 一种控释制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE257012T1 (de) | 2004-01-15 |
| CN1244327C (zh) | 2006-03-08 |
| PE20001395A1 (es) | 2000-12-23 |
| PL337867A1 (en) | 2000-07-31 |
| AR022254A1 (es) | 2002-09-04 |
| ZA200000173B (en) | 2000-08-07 |
| HU0000138D0 (en) | 2000-03-28 |
| HUP0000138A2 (hu) | 2001-02-28 |
| DE19901687A1 (de) | 2000-07-20 |
| EP1020185A3 (de) | 2000-09-27 |
| AU1011300A (en) | 2000-07-20 |
| IL134076A (en) | 2005-05-17 |
| SK642000A3 (en) | 2000-08-14 |
| DE59908195D1 (de) | 2004-02-05 |
| SK285129B6 (sk) | 2006-07-07 |
| AU771064B2 (en) | 2004-03-11 |
| SI1020185T1 (en) | 2004-04-30 |
| EP1020185A2 (de) | 2000-07-19 |
| EP1020185B1 (de) | 2004-01-02 |
| HK1029749A1 (zh) | 2001-04-12 |
| CO5251462A1 (es) | 2003-02-28 |
| ES2213971T3 (es) | 2004-09-01 |
| HUP0000138A3 (en) | 2001-03-28 |
| US6685964B1 (en) | 2004-02-03 |
| IL134076A0 (en) | 2001-04-30 |
| JP2000212072A (ja) | 2000-08-02 |
| CA2295471A1 (en) | 2000-07-18 |
| DK1020185T3 (da) | 2004-02-16 |
| PT1020185E (pt) | 2004-05-31 |
| NZ502261A (en) | 2001-11-30 |
| DE19901687B4 (de) | 2006-06-01 |
| RU2239417C2 (ru) | 2004-11-10 |
| KR20000071247A (ko) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1244327C (zh) | 可控释活性物质的阿片样止痛药 | |
| RU2141822C1 (ru) | Новые гранулы для регулируемого высвобождения и фармацевтические препараты, содержащие такие гранулы | |
| AU772886B2 (en) | Medicinal formulations containing an opioid and an alpha-antagonist | |
| US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| CN102325526B (zh) | 延长释放的药物制剂 | |
| CZ298694A3 (en) | Preparation containing morphine salt with controlled release | |
| AU777330B2 (en) | Analgesic with controlled active substance release | |
| JP5948648B2 (ja) | 安定化されたエペリゾンを含有する徐放性製剤 | |
| SK50442006A3 (sk) | Pelety obsahujúce hydrochlorid venlafaxínu | |
| CN1153475A (zh) | 具有活性物质缓释特性的卡巴捷平药物 | |
| WO2006045152A1 (en) | Improved tabletting process | |
| JPH10218762A (ja) | 放出制御型マトリックス錠及びその製造方法 | |
| MXPA00000604A (en) | Opioid analgesics with controlled release | |
| AU2005299253B2 (en) | Improved tabletting process | |
| AU708408B2 (en) | Analgesic immediate and controlled release pharmaceutical composition | |
| HK1029749B (zh) | 具有控制释放之鸦片啶止痛剂 | |
| CN101491505A (zh) | 盐酸罗匹尼罗缓释制剂及其制备方法 | |
| CZ2000171A3 (cs) | Orálně aplikovatelný preparát opioidních analgetik s kontrolovaným uvolňováním účinné látky |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060308 Termination date: 20140117 |